Quantitative analysis of primaquine and its metabolites in human urine using liquid chromatography coupled with tandem mass spectrometry

Khan, Washim; Wang, Yan-Hong; Nanayakkara, NP Dhammika; Herath, H. M. T. Bandara; Chaurasiya, Narayan D.; Tekwani, Babu L.; ElSohly, Mahmoud A.; McChesney, James D.; Khan, Ikhlas A.; Walker, Larry

doi:10.1016/j.jchromb.2022.123517

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different metabolites of PQ and internal standards were synthesized at the National Center for Natural Products Research, University of Mississippi. Synthesis of reference standards have been described in the previous article; primaquine-5,6-orthoquinone (POQ) ( Potter et al, 2015 ), carboxyprimaquine-5,7-orthoquinone (cPOQ) ( Khan et al, 2021 ), PQ-N-CG ( Fasinu et al, 2016 ), cPQ ( McChesney and Sarangan, 1984 ), 4-methylprimaquine-5,6-orthoquinone (4-MePOQ), and deuterated primaquine (d3-PQ) ( Khan et al, 2022b ). The racemic PQ, PQ enantiomers and placebo capsules used for the clinical study were prepared with complete characterization, purity, and stability, by ElSohly Laboratories, Inc (ELI), Oxford, MS. Each capsule contained the desired specific amount of PQ base as the diphosphate salt.…”

Section: Methodsmentioning

confidence: 99%

Comparative metabolism and tolerability of racemic primaquine and its enantiomers in human volunteers during 7-day administration

et al. 2023

Self Cite

View full text Add to dashboard Cite

Primaquine (PQ) is an 8-aminoquinoline antimalarial, active against dormant Plasmodium vivax hypnozoites and P. falciparum mature gametocytes. PQ is currently used for P. vivax radical cure and prevention of malaria transmission. PQ is a racemic drug and since the metabolism and pharmacology of PQ’s enantiomers have been shown to be divergent, the objectives of this study were to evaluate the comparative tolerability and metabolism of PQ with respect to its two enantiomers in human volunteers in a 7 days’ treatment schedule. Fifteen subjects with normal glucose-6-phosphate dehydrogenase (G6PDn) completed four arms, receiving each of the treatments, once daily for 7 days, in a crossover fashion, with a 7–14 days washout period in between: R-(−) enantiomer (RPQ) 22.5 mg; S-(+) enantiomer (SPQ) 22.5 mg; racemic PQ (RSPQ) 45 mg, and placebo. Volunteers were monitored for any adverse events (AEs) during the study period. PQ and metabolites were quantified in plasma and red blood cells (RBCs) by UHPLC-UV-MS/MS. Plasma PQ was significantly higher in SPQ treatment group than for RPQ. Carboxy-primaquine, a major plasma metabolite, was much higher in the RPQ treated group than SPQ; primaquine carbamoyl glucuronide, another major plasma metabolite, was derived only from SPQ. The ortho-quinone metabolites were also detected and showed differences for the two enantiomers in a similar pattern to the parent drugs. Both enantiomers and racemic PQ were well tolerated in G6PDn subjects with the 7 days regimen; three subjects showed mild AEs which did not require any intervention or discontinuation of the drug. The most consistent changes in G6PDn subjects were a gradual increase in methemoglobin and bilirubin, but these were not clinically important. However, the bilirubin increase suggests mild progressive damage to a small fraction of red cells. PQ enantiomers were also individually administered to two G6PD deficient (G6PDd) subjects, one heterozygous female and one hemizygous male. These G6PDd subjects showed similar results with the two enantiomers, but the responses in the hemizygous male were more pronounced. These studies suggest that although the metabolism profiles of individual PQ enantiomers are markedly different, they did not show significant differences in the safety and tolerability in G6PDn subjects.

show abstract